Bridges Benjamin, Hussain Arif
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Curr Opin Oncol. 2007 May;19(3):222-8. doi: 10.1097/CCO.0b013e3280ad43df.
Preclinical and clinical developments in germ cell tumors over the past year are summarized.
Attenuations in the rising incidence of testicular germ cell tumors are beginning to be observed in certain European populations. Additional data on predisposing factors related to race, estrogenic exposure, cryptorchidism, and infertility are becoming available. Significant work on the genetic and molecular alterations in tissue specimens and cell culture models of germ cell tumors continues. Additional treatment strategies for advanced stages of the disease are being evaluated. Cardiovascular and metabolic consequences of therapies in long-term testicular germ cell tumor survivors are being further clarified. Late relapses of successfully treated patients are also being increasingly recognized.
More effective treatments for intermediate risk, poor risk, and recurrent germ cell tumors need to be developed, while long-term toxicities of therapies need to be further modified. Given these challenges, active research on these fronts continues and remains a priority.
总结过去一年生殖细胞肿瘤的临床前和临床进展。
在某些欧洲人群中，已开始观察到睾丸生殖细胞肿瘤发病率上升趋势的减缓。关于种族、雌激素暴露、隐睾症和不育症等易感因素的更多数据也已可得。针对生殖细胞肿瘤组织标本和细胞培养模型中的基因及分子改变的重要研究仍在继续。针对该疾病晚期的更多治疗策略正在评估中。睾丸生殖细胞肿瘤长期幸存者治疗的心血管和代谢后果正在进一步明确。成功治疗患者的晚期复发也越来越受到关注。
需要开发针对中危、高危和复发生殖细胞肿瘤更有效的治疗方法，同时进一步改善治疗的长期毒性。鉴于这些挑战，这些方面的积极研究仍在继续且仍是优先事项。
